Aclaris Therapeutics Inc. said on Monday its experimental drug failed to meet the main goal of a mid-stage study to treat a painful skin disorder, sending its shares tumbling more than 36% in premarket trading.
https://www.pharmalive.com/wp-content/uploads/2023/03/Aclarislogo.jpeg200200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-06 08:54:272023-03-06 10:22:45Aclaris shares tank as skin disorder drug fails mid-stage study
